SOLA Biosciences
SOLA Biosciences is a pre-clinical-stage biopharmaceutical company dedicated to developing gene therapies for neurodegenerative diseases such as ALS, Huntington's disease, and Alzheimer's disease. Their innovative JUMP70 platform technology harnesses the power of patient’s own chaperones to repair misfolding proteins, aiming to provide transformative treatments for conformational diseases.
Industries
Nr. of Employees
small (1-50)
Products
Gene therapy candidate targeting misfolded TDP-43 for ALS
A preclinical gene therapy designed to selectively eliminate or repair misfolded TDP-43 species in motor neurons via recruitment of the Hsp70 chaperone system; demonstrated target engagement and survival benefit in ALS mouse models.
Gene therapy candidate targeting polyglutamine-expanded Huntingtin for Huntington's disease
A preclinical gene therapy designed to selectively target the expanded polyQ misfolded domain of Huntingtin protein to correct folding defects or promote degradation without affecting wild-type Huntingtin.
Gene therapy candidate targeting misfolded TDP-43 for ALS
A preclinical gene therapy designed to selectively eliminate or repair misfolded TDP-43 species in motor neurons via recruitment of the Hsp70 chaperone system; demonstrated target engagement and survival benefit in ALS mouse models.
Gene therapy candidate targeting polyglutamine-expanded Huntingtin for Huntington's disease
A preclinical gene therapy designed to selectively target the expanded polyQ misfolded domain of Huntingtin protein to correct folding defects or promote degradation without affecting wild-type Huntingtin.
Services
Preclinical gene therapy research and development
Design and preclinical evaluation of gene therapy candidates that use engineered proteins to selectively engage cellular chaperone systems for correction or removal of misfolded intracellular proteins.
Preclinical gene therapy research and development
Design and preclinical evaluation of gene therapy candidates that use engineered proteins to selectively engage cellular chaperone systems for correction or removal of misfolded intracellular proteins.
Expertise Areas
- Gene therapy development
- Proteostasis modulation and chaperone-based therapeutics
- Preclinical efficacy testing in neurodegenerative disease models
- AAV vector delivery for CNS targets
Key Technologies
- AAV-mediated gene delivery
- Chaperone (Hsp70) recruitment and proteostasis modulation
- Targeted protein-binding domain engineering
- Preclinical cell-based assays